

# Genotype-phenotype relationship in patients with *SHOX* region rearrangements detected by MLPA in the French population

Julie AUGER<sup>1</sup>, Amandine BAPTISTE<sup>2</sup>, Gaëlle THIERRY<sup>3</sup>, Jean-Marc COSTA<sup>4</sup>, Mélanie AMOUYAL<sup>5</sup>, Marie-Laure KOTTLER<sup>6</sup>, Renaud TOURAINE<sup>7</sup>, Marine LEBRUN<sup>7</sup>, Bruno LEHEUP<sup>1</sup>, Sébastien SCHMITT<sup>3</sup>, Valérie CORMIER-DAIRE<sup>8</sup>, Jean-Paul BONNEFONT<sup>8</sup>, Caroline ELIE<sup>2</sup>, Nicolas DE ROUX<sup>5</sup>

<sup>1</sup> Médecine infantile et Génétique clinique - CHU Nancy, <sup>2</sup> Unité de recherche clinique - CHU Necker enfants malades - Paris, <sup>3</sup> Laboratoire de Génétique - CHU Nantes, <sup>4</sup> Laboratoire CERBA - Saint Ouen l'Aumône, <sup>5</sup> Laboratoire de Génétique - CHU Robert Debré - Paris, <sup>6</sup> Laboratoire de Génétique - CHU Caen, <sup>7</sup> Laboratoire de Génétique - CHU Saint-Etienne, <sup>8</sup> Laboratoire de Génétique- CHU Necker enfants malades - Paris

**Background :** *SHOX* and enhancer regions on PAR1 disorders have variable phenotypic consequences such as idiopathic short stature (ISS) and Leri-Weill Dyschondrosteosis (LWD).

**Objective and hypotheses :** The aim of this observational multicentric study was to describe phenotypes and genotypes of a large population with mutation on *SHOX* and adjacent regions and to identify a possible phenotype-genotype correlation.

## Materials and methods

- **National multicentric observational study**
- **Selection criterion :** presence of a rearrangement of *SHOX* gene and/or its regulatory region in PAR 1 (a deletion or a duplication, upstream or downstream of the gene in enhancer regions) detected with MLPA.
- **Method :** phenotypes and genotypes were collected between 2009 and 2013 in 7 French laboratories using MLPA (Multiplex Ligation - dependant PCR Analysis) for diagnosis (Paris-Necker, Paris-Robert Debré, Nancy, Cerba, Nantes, Saint-Etienne, Caen).

TABLE 1. General clinical characteristics of the population (n=305)

Patients characteristics		MD (%)
Age (Q1; Q3)	13,3 (9.4; 3.2)	4 (1.3)
Gender (F/M) (%*)	196/109 (64.3/35.7)	0
Maternal height (DS) (Q1; Q3)	-1,6 (-2.4;-0.6)	91 (27.9)
Paternal height (DS) (Q1; Q3)	-1,1(-2.2;-0.1)	92 (30)
Target height (DS) (Q1; Q3)	-1,3 (-2.0;-0.8)	106 (34.7)
Deviation from the target height (cm) (Q1; Q3)	-3,7(-7.7;-1.0)	65 (58.5)**
Height (DS) (Q1; Q3)	-2,2 (-2.8;-1.5)	30 (9.8)
<b>Phenotype</b>		
No sign (%)	9 (3.7)	
ISS (%)	12 (4.9)	63 (2.6)
LWD (%)	221 (91.3)	
Growth retardation (%)	183 (63.7)	18 (5.9)
Madelung deformity (%)	124 (48.4)	49 (16.06)
Mesomelia (%)	149 (61.6)	63 (20.6)
Radiological signs (%)	169 (84.9)	106 (34.7)

MD: missing data

\* of total population with available data

\*\* of population aged more than 18 yrs

TABLE 2. Comparison of the population according to gender (n=305)

	Girls	Boys	p
Age (yrs) [Q1;Q3]	12,7 [9.2; 30.8]	15,2 [10.6; 40.8]	<b>0.038</b>
Index cases (%)	145 (71)	61 (29)	<b>0.0007</b>
Population < 18 yrs (%)	126 (41.3 %)	64 (21 %)	
Population > 18 yrs (%)	69 (22.6 %)	42 (13.8 %)	
Height (DS) [Q1;Q3]	-2,4 [-3.0; -1.7]	-2,0 [-2.4; -1.4]	<b>0.007</b>
Target height (DS) [Q1;Q3]	-1,5 [-2.0; -0.8]	-1,2 [-1.8; 1.2]	0.158
No sign (%)	3 (1.8*)	6 (8.0**)	
ISS (%)	10 (6.0*)	2 (2.7**)	<b>0.044</b>
LWD (%)	154 (92.2*)	67 (89.3**)	
Madelung deformity (%)	97 (56.4*)	27 (32.1**)	<b>0.0004</b>
Growth retardation (%)	129 (68.6*)	54 (54.5**)	<b>0.018</b>
Mesomelia (%)	109 (67.7*)	40 (49.4**)	<b>0.005</b>
Radiological signs (%)	112 (84.2*)	57 (86.4**)	0.68

\* of girls \*\* of boys

## Results - discussion

- **205 Index Cases** (IC; 74% females) and **100 Related Cases** (RC; 26% females) were diagnosed
- 91.3 % had phenotype of LWD
- Median age at diagnosis was 11.7 yrs in IC [Q1:9.0; Q3:15.9] and 38 yrs in RC [Q1: 14.1; Q3: 43.8].
- Median height SDS was -2.2 in IC [Q1: -2.9; Q3: -1.7] and -1.8 in RC [Q1: -2.4; Q3: -0.8].
- Girls were diagnosed earlier than boys (12.7 yrs vs 15.2 yrs, p=0.04)
- Girls were shorter (-2.4 DS vs -2.0 DS, p=0.007) and presented more frequently with Madelung deformity (78.2 % vs 21.7%, p=0.0004)
- Genetic anomalies were :
  - 40.3% *SHOX* +/- PAR 1 deletions
  - 33.7 % PAR 1 deletions
  - 5.9 % PAR 1 duplications
  - 2.0 % *SHOX* + PAR 1 duplications
  - 18 % point mutations
- In girls, deletions were more frequently associated with Madelung deformity, short forearm and radiologic anomalies than duplications (p=0.02, p=0.006 and p=0.008 respectively).

## Conclusions

Our study is the first nationwide description of *SHOX* patients population diagnosed with MLPA and the first study concerning phenotype - genotype relationship of *SHOX* in a large national population. While most of past studies treated the prevalence of *SHOX* deficit, our study was set up to study only patients with anomalies in *SHOX* and adjacent regions, and to find a correlation between phenotype and the different genotypes in this group.

We highlighted a smaller proportion of Madelung deformity, short forearm and radiological signs, in duplications than in deletions, especially in girls. Both growth retardation and skeletal features observed tend to be more severe in girls. The severity of the phenotype in girls contributes to the highest proportion of female subjects diagnosed.

